Introduction
The population in the United Kingdom is ageing. In 1981 just 1% of the population was aged 85 years and over, but in the last 25 years the number has doubled to 1.2 million and is expected to further increase to 2.9 million by 2031. A total of 4% of the UK population will then be 85 years or more. 1 As the population ages, more patients are expected to develop chronic age-related conditions such as hypertension. At present, it is estimated that more than 50% of the 12 million people in the UK over 60 years are hypertensive, even when a relatively high threshold (X160/95 mm Hg) is used for diagnosis. 2 Until recently, it was unclear whether the treatment of very elderly hypertensive patients, that is, those of 80 years or more, conferred more benefit than risk. Many trials in the past have either excluded such patients, or have recruited too few to show benefit of treatment. A subgroup meta-analysis of randomized trials suggested that treatment of hypertension in this group resulted in a 36% reduction in stroke but an increased risk of death from any cause. 3 A further retrospective cohort study demonstrated lower survival rates in patients in their eighties with systolic blood pressures of o140 mm Hg on antihypertensive treatment. 4 The findings of the Hypertension in the Very Elderly trial (HYVET), however, have led to a re-evaluation of the clinical management of hypertension in this group of patients. 5 This double-blind, placebo-controlled multi-centre trial, randomly assigned 3845 patients aged 80 years and above, with a sustained systolic blood pressure of X160 mm Hg to indapamide (sustained release 1.5 mg, with or without perindopril) or placebo, to achieve a target blood pressure of 150/80 mm Hg. Treatment was associated with a 30% reduction in fatal or non-fatal stroke (95% confidence interval (CI)À1-50, P ¼ 0.06), a 21% reduction in the mortality rate from any cause (95% CI, 4-35, P ¼ 0.02), a 23% reduction in the rate of death from cardiovascular disease (95% CI, À1-40, P ¼ 0.06), and a 64% reduction in the rate of heart failure (95% CI, 42-78, P ¼ 0.001). Of note, there were fewer reported adverse events in the treatment group.
These findings support the hypothesis that treatment of hypertension should include the very elderly at least to a target blood pressure of 150/ 80 mm Hg, but this may pose difficulties in practice. Older people with hypertension often have several other co-existing medical conditions, for which they may be taking multiple medications. This increases the risk of drug interactions and adverse effects with antihypertensives. Increasing age is also associated with changes in pharmacokinetics and pharmacodynamics, impaired cardiac, renal and baroreceptor function, and cognitive impairment, all of which can make prescribing in this age group challenging. [6] [7] [8] The aim of this study was to determine whether development of or the potential risk of adverse drug reactions (ADRs) to antihypertensive drugs limits the clinician's ability to follow guidelines and achieve blood pressure targets in the very elderly. Ambulatory blood pressure monitoring (ABPM) was used to assess blood pressure control at the time of referral to a hospital hypertension service. We then assessed whether the presence of ADRs limited our ability to act on the results of the ABPM to improve control.
Materials and methods
We conducted a retrospective cohort study to identify hypertensive patients aged 80 years or over who had attended the Hypertension Research Clinic, Wellcome Clinical Research Facility, University Hospital Birmingham over a 10-year period. This clinic runs as a part of the Hypertension Service and deals with 500 new referrals per year. All patients have ambulatory blood pressure monitoring carried out as a part of the routine clinical service.
Patients were identified either from a database of hypertensive patients attending the clinic (Microsoft Access 2002), or from clinic letters and medical records dating from 1998 when the clinic was set up. For the purpose of this study the following data were extracted for patients aged 80 years or over: reason for referral to the hypertension clinic, clinic blood pressure readings, mean daytime and nighttime 24 h ABPM readings, current antihypertensive medications, clinical diagnosis and changes in medications or recommendations on management made after the clinic appointment.
On the basis of the ambulatory blood pressure monitoring data all patients were categorized according to the thresholds and targets used in the HYVET study. The mean daytime blood pressure was the principle parameter used to categorize blood pressure. An adjustment upward of 10 mm Hg systolic and 5 mm Hg diastolic was made to the mean daytime readings to allow for the differences in home and office readings in accordance with British Hypertension Society Guidelines. 3 Thus, in unmedicated patients a diagnosis of hypertension was made if the mean daytime ABPM systolic reading was X150 mm Hg. This corresponded with the threshold of 160 mm Hg used in the HYVET study. Patients who were already on treatment at the time of the clinic referral were considered to have well-controlled blood pressure if their mean day time ABPM was o140/75 mm Hg or poorly controlled blood pressure if it was X140/75 mm Hg. This corresponds to the target of 150/80 mm Hg used in the HYVET study. For those patients whose blood pressure was higher at night, the mean nighttime pressures were used for analysis. For the purposes of the analysis taking the HYVET targets into account, unmedicated patients were considered to have 'white coat' hypertension if the mean ambulatory blood pressure was o140/75 mm Hg but the first few readings (or clinic readings) were 4150 mm Hg. Patients on antihypertensive treatment were considered to be over medicated if the mean day time systolic pressure was o130 mm Hg systolic.
Results
We identified a sample of 100 patients who were aged 80 years or over at the time of referral, between April 1998 and May 2008. A small number of patients were excluded because of missing data. The age range was 80-94 years, with a mean age of 83 years. The commonest reason for referral to the hypertension clinic was 'difficult to control hypertension'.
The diagnostic codes assigned to patients based on their mean daytime ABPM readings are outlined in Figure 1 . Most (64 out of 100) patients were diagnosed with 'poorly controlled blood pressure' on the basis of ABPM (mean daytime pressure X140/75 mm Hg). This was despite the treatment in 57 patients. A total of 6 unmedicated patients were found to have confirmed hypertension and 1 patient was unmedicated, despite having poorly controlled BP, owing to adverse effects.
Of the 64 'poorly controlled patients', 38 patients were appropriately started on an additional antihypertensive according to the British Hypertension Society guidelines 3 or had the dose of an existing antihypertensive increased. In 17 additional patients an additional agent was added to reduce the blood pressure, but one (or more) of their existing hypertensives were either stopped or the dose reduced, predominantly as a result of ADRs. Eight Effect of ADRs on achieving targets TF Butt et al patients had no change made to their medications despite poor control because previous ADRs precluded further intervention (Figure 2 ), in addition one confirmed hypertensive remained unmedicated because of ADRs. Some problems limiting treatment options in this group included ankle oedema secondary to amlodipine, adverse effects secondary to beta-adrenoceptor blockers, and large variability in blood pressure on ABPM, increasing the risk of hypotensive episodes with addition of further therapy (Table 1) . Finally, 12 patients in the poorly controlled group had a marked 'white coat' effect identified on the ABPM, which would have led to aggressive escalation of therapy if surgery and/or clinic readings were used to guide management.
An additional 36 of 100 patients, who were on antihypertensive medication at the time of referral to clinic, did not warrant any further intervention as the blood pressure was well-controlled (28 patients) or too tightly controlled (4 patients) on ambulatory monitoring.
A 'white coat' effect was identified in 17 of these patients. Furthermore, four unmedicated patients were diagnosed with 'white coat' hypertension and did not need treatment (Figure 1 ). Of the 28 elderly patients, whose blood pressure was well-controlled on treatment, 13 had no change made to their treatment. Half of the patients from this group (14 out of 28), however, had an antihypertensive agent stopped and/or reduced owing to ADRs, despite good blood-pressure control (Figure 3 ). Reported ADRs included ankle oedema (calcium-channel blockers), headache (ACE inhibitor), cold extremities and bradycardia (beta-adrenoceptor blockers), hyponatremia (ARBs), and worsening renal function (ARB, ACE-inhibitor and thiazide diuretics) ( Table 2 ). Seven patients, who had an antihypertensive agent stopped, were started on an alternative agent in its place. The four patients who had low blood pressure on ABPM had an antihypertensive agent stopped to avoid postural symptoms.
Poorly controlled BP (64)
Antihypertensive stopped due to ADRs (15) Antihypertensive dose reduced due to ADRs
No change made due to ADRs (9) Figure 2 Influence of ADRs on management of patients with poorly controlled blood pressure. Figure 1 Diagnoses at clinic based on mean daytime ABPM reading. Figure 3 Influence of ADRs on management of patients with well-controlled blood pressure.
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Discussion
This study highlights the difficulties of treating patients of 80 years and over with antihypertensives even when the target blood pressure is relatively modest (150 mm Hg). Almost half the patients had documented ADRs, which limited further intervention (40 out of 100) or had very low blood pressure that necessitated withdrawal of therapy (4 patients) to avoid troublesome postural symptoms. The results suggest that aggressive treatment of hypertension in the very elderly may be difficult to achieve in practice, because of the high incidence of ADRs and poor tolerability of drugs in this age group. There are several reasons why older people may be more vulnerable to adverse drug reactions including age-related changes in pharmacokinetics and pharmacodynamics, impaired cardiac, renal and baroreceptor function, and cognitive impairment. [6] [7] [8] Several studies have confirmed the high incidence of ADRs in elderly patients taking antihypertensives, and these agents are a frequent cause of ADRs leading to hospital admission. 9, 10 Polypharmacy is common in the elderly and can increase the risk of drug interactions and adverse events as a consequence. The prevalence of postural or orthostatic hypotension has been reported to be between 10 and 30% for elderly people and is particularly associated with the use of antihypertensive medication. 11 Reduced renal clearance of various drugs including antihypertensives, can increase plasma levels and thus increase the risk of toxicity. 12 Poor compliance with antihypertensive therapy can also be a problem in managing elderly patients with hypertension. Non compliance with drug therapy is reported to occur in around 30-50% of elderly patients. 13 A number of factors can contribute to poor compliance, including poor communication with healthcare professionals, decline in cognitive or physical function and complicated dosage regimens.
The HYVET study provided compelling evidence that hypertension treatment based on indapamide with or without perindopril in the very elderly aiming for a target of 150/80 mm Hg is beneficial. Active treatment was associated with impressive reductions in stroke rates, deaths from any cause and heart failure. There was a very low incidence of trial medication-related adverse events. 1 In our study of patients of 80 years or over attending a hospital-based hypertension clinic; however, problems with ADRs were common and in many cases limited the ability to treat to target.
Our findings also demonstrated that diagnoses based on office readings in the community rather than average day time ambulatory readings, would have led to inappropriate escalation of medication in a significant proportion of our elderly patients, many of whom had a marked 'white coat' effect. This confirms how useful 24 h ABPM can be, even in the very elderly, who tolerated the procedure surprisingly well. The use of ABPM in the diagnosis and monitoring of hypertension has increased in recent years and has led to improvements in blood pressure measurement. In addition, ABPM has been shown to be a better predictor of cardiovascular mortality and end organ damage and is the only way to identify 'non-dippers'.
14 Our findings are in keeping with the Second Australian National Blood Pressure Study, which showed that the mean daytime ABPM readings were lower than clinic readings in a large cohort of untreated elderly hypertensives, although a substantial proportion also showed a reverse 'white coat' effect. 15 Further results from the HYVET study in relation to cardiovascular outcomes and ambulatory data in the very elderly are awaited. 16 
Conclusion
In conclusion, our study highlights the challenge of prescribing antihypertensive medication in very elderly patients and suggests that a high incidence of ADRs may preclude treatment to a target of 150 mm Hg. It also suggests that ambulatory monitoring may have a role in managing these patients, particularly for individuals experiencing difficulties with their medication. The study is limited by the fact that the patients included were attending a hospital (2) clinic because of poorly controlled blood pressure, so may not be representative of very elderly patients managed in primary care. Nonetheless, the findings suggest that careful monitoring of very elderly patients taking antihypertensive agents is needed.
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